Annabelle Samimi
Analyst
Stifel
Equibles does not estimate personal net worth.
About Annabelle Samimi
Annabelle Samimi is recorded as Analyst at Stifel. Annabelle Samimi has spoken on 18 earnings calls and 1 other investor event across 11 companies, most recently for Altimmune, Inc. on August 12, 2026. Those appearances were for Phathom Pharmaceuticals, Inc. (PHAT), Ligand Pharmaceuticals Inc (LGND), Evolus, Inc. (EOLS), Altimmune, Inc. (ALT), Trevi Therapeutics, Inc. (TRVI) and 6 other companies. The companies whose calls Annabelle Samimi spoke on are classified in the Healthcare sector.
Annabelle Samimi on recent calls
“So I'm curious about the follow-up from the AUD study. So I think it's pretty well known that with the weight loss drugs, there's rebound when patients stop taking the injections and there's persistence problems.”
“Just wanted to clarify on the SSRE for your programs. Is it only going to be for the lake program or are you also doing it for the ocean programs Hey, Annabelle, it's Jim.”
“So for what AMD as you approach data, I know most of these physicians are retinal surgeons and perform vitrectomies, but how many physicians would you say have already been trained on your procedure specifically, and can you remind us how many patients have opted for bilateral treatment?”
“So the composition of your royalty assets now post-DOMA seems to have really stepped up quite a bit. And it might be hard to move the needle now with additional one-off product deals.”
“I'm really interested in your new licensing of Profilo for skin quality. As usual, U.S. is catching up with international markets. I want to understand this product a little better.”
Affiliation history
-
Stifel
Analyst
Transcript header (unverified)
Current
Company network
EOLS
Drug Manufacturers - Specialty & Generic · Healthcare
ALT
Biotechnology · Healthcare
RGNX
Biotechnology · Healthcare
Drug Manufacturers - Specialty & Generic · Healthcare